New Sight Loss Firm KalVista Is Launched

KalVista Pharmaceuticals, a new ophthalmology company based in the UK, with a focus on diabetic macular edema (DME) has raised £8 million, helped by the investment arm of Novo Nordisk, to develop its ophthalmology research. The cash comes from a series A round from Novo A/S and SV Life Sciences and the funds will be

Continue Reading